A fluorophotometric study of corneal endothelium after trabeculectomy using different concentrations of Mitomycin-C.
The aim of the study was to determine the corneal endothelial permeability coefficient (Pac) in subjects after trabeculectomies using different concentrations of Mitomycin-C (MMC). MMC, a highly toxic drug, is not without drawbacks and complications such as corneal damage. To ascertain a possible relationship between a level of endothelial permeability (Pac) and concentrations of MMC used, we performed, in a prospective study, trabeculectomies in cases of primary open-angle glaucoma (POAG), younger than 50 years, with either concentrations of 0.5 mg/ml of MMC (group 1: 11 eyes) or 0.2 mg/ml of MMC (group 2: 10 eyes). Group 3 consisted of 8 patients after a typical trabeculectomy without MMC and served as a control group (8 eyes). In all groups, before surgery and again 1, 3 and 6 months after surgery, corneal endothelial permeability (Pac) was determined by using anterior segment fluorophotometry (Fluorotron Master). The thickness of the cornea (CT) was measured with a DGH Technology ultrasonic pachymeter. One month after surgery the mean values of Pac were statistically significantly higher in groups 1 and 2 (group 1: 4.78 x 10(-4) cm/min, group 2: 4.67 x 10(-4) cm/min) in comparison with the control group (group 3: 3.37 x 10(-4) cm/min), but the differences between groups 1 and 2 were not statistically significant (p = 0.05). Six months after operation the mean values of Pac in all groups were normalized. In eyes that underwent trabeculectomy with MMC, higher concentrations of MMC were likely to have a transient adverse effect on corneal endothelial permeability. In light of the resulting toxic intraocular effect of MMC, the damage in the function of the corneal endothelial barrier is greater with greater concentrations of MMC.
Szymanski
A
A
Silesian School of Medicine, Department of Ophthalmology, Poland.
Gierek-Lapinska
A
A
Koziak
M
M
Gierek-Ciaciura
S
S
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D002463:Cell Membrane Permeability / Q000187:drug effects; D017024:Chemotherapy, Adjuvant; D004305:Dose-Response Relationship, Drug; D004728:Endothelium, Corneal / Q000098:blood supply / Q000378:metabolism*; D005260:Female; D019793:Fluorescein; D005452:Fluoresceins; D015590:Fluorophotometry; D005902:Glaucoma, Open-Angle / Q000378:metabolism* / Q000601:surgery; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D014130:Trabeculectomy
D000903:Antibiotics, Antineoplastic; D005452:Fluoresceins; D009883:Ophthalmic Solutions; D016685:Mitomycin; D019793:Fluorescein